Patients generally seem happy with their GLP-1 injections
Na + -D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion
GLP-1s may activate brain receptors involved in circadian rhythm Emerging research points to mechanisms that go beyond weight loss to improve sleep
Full-dose GLP-1 therapy can sometimes be associated with low energy during early use
Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease
"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA." The New England Journal of Medicine, 2023